Corbus Q4 net loss $10.9M; COO Craig Millian departing; CRB-701 ADC licensed from CSPC

Corbus Pharmaceuticals Holdings, Inc.

Net loss for Q4 2022 was $10.9M ($2.61/diluted share); FY2022 net loss $42.3M ($10.15/diluted share).
Cash and investments of $59.2M as of Dec 31, 2022, expected to fund operations through Q2 2024.
COO Craig Millian resigned effective April 14, 2023 to pursue other opportunities.
Licensed CRB-701 (Nectin-4 ADC) from CSPC; Phase 1 dose escalation ongoing in China for advanced solid tumors.
CRB-601 (anti-αvβ8 mAb) IND submission scheduled for H2 2023; first patient expected by end of 2023.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Craig Millian

Chief Operating Officer

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2023-04-14
Filed: March 7, 2023, 6:59 PM ET

On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Corbus Pharmaceuticals Holdings, Inc. reported the three months ended December 31, 2022 results: net income a net loss of approximately $10.9 million, EPS a net loss per diluted share of $2.61.

Period: the three months ended December 31, 2022
Net income: a net loss of approximately $10.9 million
EPS: a net loss per diluted share of $2.61
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the three months ended December 31, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Corbus Pharmaceuticals Holdings, Inc. reported the year ended December 31, 2022 results: net income a net loss of approximately $42.3 million, EPS a net loss per diluted share of $10.15.

Period: the year ended December 31, 2022
Net income: a net loss of approximately $42.3 million
EPS: a net loss per diluted share of $10.15
Result: reported results

Exact text from the filing

For the year ended December 31, 2022, the Company reported a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Craig Millian resigned as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc..

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

On March 3, 2023, Craig Millian, Chief Operating Officer of the Company, submitted a notice of resignation to the Company to pursue other opportunities.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006385

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.